Scientific article
OA Policy
English

Brain and plasmatic CLUSTERIN are translational markers of Alzheimer's disease

Published in

Brain pathology, e13281

First online date

2024-06-22

Abstract

Early diagnosis of late‐onset Alzheimer's disease (AD) by peripheral biomarkers remains a challenge; many have been proposed, but none have been evaluated in a prospective manner. CLUSTERIN (CLU), a chaperone protein expressed in the brain and found in relatively high concentrations in plasma, is a promising candidate. CLU contributes to the elimination of β‐amyloid (Aβ), which is associated to neurofibrillary tangles and to the genetic risk for AD. We performed a longitudinal measurement of CLU in the brain and the plasma in 3xTgAD mice. Assessment of CLU was also conducted in 12‐month‐old TgF344‐AD rats. In humans, brain CLU was measured in non‐demented and in AD subjects. The plasma CLU was longitudinally measured in four cohorts defined as healthy controls that remained stable, healthy controls that presented a cognitive decline between the two measures, mild cognitive impairment (MCI) that presented a cognitive decline between the two measures and AD. A validation cohort composed of 19 MCI was used and plasma CLU was measured before and after conversion in AD. Increases in CLU were measured in the hippocampus of 3xTgAD and TgF344‐AD animals in the absence of plasmatic changes. CLU is heterogeneously expressed in the hippocampus in non‐demented individuals and increased in AD. In the plasma, two CLU levels were measured: low in controls and MCI, and high in AD. To validate that the elevation in CLU is associated with conversion to AD, a replication study showed, in a second group MCI patients converting to AD in the follow‐up that CLU levels increased in 16/19 individuals. The increase in brain CLU occurs in AD models as in humans, and seems to precede plasma variations, which could make it an AD therapeutic target. Plasma CLU seems to be a promising marker of cognitive decline, and its association with AD may be a useful complementary diagnostic tool.

Citation (ISO format)

TOURNIER, Benjamin et al. Brain and plasmatic CLUSTERIN are translational markers of Alzheimer’s disease. In: Brain pathology, 2024, p. e13281. doi: 10.1111/bpa.13281

Main files (1)

Article (Published version)

Secondary files (1)

Appendix - Supplemental Figures 1-3

Identifiers

Journal ISSN

1015-6305
113views
154downloads

Technical informations

Creation

27/06/2024 11:21:02

First validation

16/07/2024 11:49:45

Update

13/10/2025 13:33:55

Status update

16/07/2024 11:49:45

Last indexation

03/11/2025 16:26:24
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated